Rexipro (Abciximab 2mg)

Each Vial 5ml contains
Composition

Abciximab .....................................................................2 mg

Indications
Platelet aggregation inhibition as adjunct to percutaneous transluminal coronary angioplasty or atherectomy (PTCA).

Description
Abciximab (c7E3) is a chimeric mouse-human monoclonal antibody directed against the GP IIb/IIIa receptor; its mechanism of action is thought to be steric hindrance of the receptor itself as opposed to direct binding to the RGD binding site of the receptor.

It also inhibits the vitronectin (av b3)receptor, which mediates both platelet coagulation as well as endothelial and vascular smooth muscle cell proliferation.

Dosage
0.25 mg/kg administered 10-60 minutes before the start of PTCA ` followed by a continuous I.V.. Injection of 10 mcg/min. for 12 hours.

Presentations
Vial 5ml